Please assess the completion status of the following clinical trial:

Trial Title: Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signature of the TCLE by participant or companion.~2. Spontaneous intracerebral hemorrhage confirmed by computed tomography or magnetic resonance imaging and fit to be included in the study and initiate therapy with study medications within 6 hours after the event.~3. Intracerebral hemorrhage (volume \< 30 cm3).~4. No immediate surgical indication.~5. Both sexes, aged above 18 years.~6. Systolic blood pressure (\> 150 mmHg and \< 220 mmHg) measured on two occasions with a minimum difference of 2 minutes.~Exclusion Criteria:~1. Cerebral hemorrhage secondary to structural lesions in the brain, vascular malformations, coagulopathies or traumatic brain injury, if known at the time of randomization.~2. Participant in deep coma, defined by the Glasgow Coma Scale score of 3 to 5.~3. Uncontrolled asthmatic or COPD participants, if known at the time of randomization.~4. Participants with Grade IV Heart Failure, defined as heart rate \< 50 beats per minute.~5. Previous hemorrhagic stroke, if known at the time of randomization~6. Participants with Cerebral Vascular Stroke.~7. Participants who have presented previous ischemic cerebrovascular accident, if known at the time of randomization.~8. Chronic diseases with life expectancy less than 3 months.~9. Score ≥ 4 on the ICH score at the time of recruitment.~10. In use of anticoagulants in the last 48 hours, if known at the time of randomization.~11. Patients with contraindication to any of the study medications.~12. Intubation Orotraqueal on arrival at the service.~13. Pheochromocytoma, if known at the time of randomization.~14. Patients with hyperthyroidism, if known at the time of randomization.~15. Known pregnancy or breastfeeding . At the discretion of the investigator, an examination for confirmation may be requested.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brevibloc, 10 Mg/mL Intravenous Solution (Type: EXPERIMENTAL): 10 mL/h every 5 minutes until reaching the pressure target
- Nitroprusside, Sodium (Type: ACTIVE_COMPARATOR): 0.5 mcg / kg / min every 3 minutes until reaching the pressure target

Based on this trial design, predict the completion outcome and termination type (if applicable).